David Antcliffe

David Antcliffe serves as a Clinical Associate Professor in Critical Medicine at Imperial College London's Department of Surgery & Cancer (Faculty of Medicine) and holds an Honorary Consultant position in Critical Care at Charing Cross Hospital. His work bridges clinical practice and academic research in critical care medicine with emphasis on sepsis phenotyping and personalized treatment approaches.

Education

• Medical Degree (MBBS), University College London, 2003
• PhD, Imperial College London, 2011-2015 (funded by Imperial College BRC and Intensive Care Foundation)

Research Interests: Dr. Antcliffe pioneers multi-omics profiling (metabonomic, transcriptomic, inflammatory) to identify sepsis sub-phenotypes for personalized critical care. His landmark finding demonstrates that sepsis response signature (SRS) transcriptomic endotypes predict corticosteroid responsiveness in septic shock, driving the CRESS project. Current work includes metabolic trajectory mapping in septic shock using VANISH/LeoPARDS trial data, post-critical illness rehabilitation via the StEADy study, and COVID-19 respiratory failure characterization through the national COVID-ICU service evaluation.

Scientific Awards

• Winner of the Intensive Care Society Research Prioritisation Exercise (2019) for CRESS project

Grants and Collaborations: Secured PhD funding from Imperial College BRC and Intensive Care Foundation. Currently leads multiple institutional projects including CRESS, Phenotyping the Patient's Journey, and StEADy through collaborations with the Centre for Antimicrobial Optimisation (BIO) and Musculoskeletal laboratory. The CRESS project aims to implement point-of-care gene expression testing for corticosteroid guidance in septic shock.

Laboratories and Teams: Core affiliate of the Centre for Antimicrobial Optimisation (BIO) and active collaborator with Imperial's Musculoskeletal laboratory, focusing on translational research from molecular phenotyping to bedside rehabilitation protocols in critical care.